Gyre Therapeutics, Inc. Income Taxes Paid
Gyre Therapeutics, Inc. (GYRE) reported Income Taxes Paid of $1.21 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaidNet · last filed 2026-05-08
- Gyre Therapeutics, Inc. income taxes paid, net for the quarter ending 2026-03-31 was $1.21M, a 63.86% decline year-over-year.
- Gyre Therapeutics, Inc. income taxes paid, net for the quarter ending 2025-12-31 was $1.13M, a 48.23% increase year-over-year.
- Gyre Therapeutics, Inc. income taxes paid, net for the quarter ending 2025-09-30 was $687.00K, a 27.93% increase year-over-year.
- Gyre Therapeutics, Inc. income taxes paid, net for the quarter ending 2025-06-30 was $447.00K, a 92.27% decline year-over-year.
- Gyre Therapeutics, Inc. income taxes paid, net for fiscal 2025 was $5.62M, a 34.01% decline from fiscal 2024.
- Gyre Therapeutics, Inc. income taxes paid, net for fiscal 2024 was $8.52M, a 34.23% increase from fiscal 2023.
- Gyre Therapeutics, Inc. income taxes paid, net for fiscal 2023 was $6.35M, a 0.63% increase from fiscal 2022.
- Gyre Therapeutics, Inc. income taxes paid, net for fiscal 2022 was $6.31M.
| Period end | Income Taxes Paid, Net 3 month | Income Taxes Paid, Net 6 month | Income Taxes Paid, Net 9 month | Income Taxes Paid, Net 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.21M 10-Q · filed 2026-05-08 | $2.34M derived: sum of 2 quarters · filed 2026-05-08 | $3.03M derived: sum of 3 quarters · filed 2026-05-08 | $3.48M derived: sum of 4 quarters · filed 2026-05-08 |
| 2025-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.81M derived: sum of 2 quarters · filed 2026-03-13 | $2.26M derived: sum of 3 quarters · filed 2026-03-13 | $5.62M 10-K · filed 2026-03-13 |
| 2025-09-30 | $687.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.13M derived: sum of 2 quarters · filed 2025-11-07 | $4.49M 10-Q · filed 2025-11-07 | $5.25M derived: sum of 4 quarters · filed 2026-05-08 |
| 2025-06-30 | $447.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $3.81M 10-Q · filed 2025-08-11 | $4.57M derived: sum of 3 quarters · filed 2026-05-08 | $5.10M derived: sum of 4 quarters · filed 2026-05-08 |
| 2025-03-31 | $3.36M 10-Q · filed 2026-05-08 | $4.12M derived: sum of 2 quarters · filed 2026-05-08 | $4.66M derived: sum of 3 quarters · filed 2026-05-08 | $10.44M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $761.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.30M derived: sum of 2 quarters · filed 2026-03-13 | $7.08M derived: sum of 3 quarters · filed 2026-03-13 | $8.52M 10-K · filed 2026-03-13 |
| 2024-09-30 | $537.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $6.32M derived: sum of 2 quarters · filed 2025-11-07 | $7.76M 10-Q · filed 2025-11-07 | $8.72M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $5.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $7.22M 10-Q · filed 2025-08-11 | $8.18M derived: sum of 3 quarters · filed 2025-08-11 | $9.56M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $1.44M 10-Q · filed 2025-05-09 | $2.40M derived: sum of 2 quarters · filed 2025-05-09 | $3.78M derived: sum of 3 quarters · filed 2025-05-09 | $7.32M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $961.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $2.34M derived: sum of 2 quarters · filed 2025-03-17 | $5.88M derived: sum of 3 quarters · filed 2025-03-17 | $6.35M 10-K · filed 2025-03-17 |
| 2023-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $4.92M derived: sum of 2 quarters · filed 2024-11-13 | $5.38M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $3.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $4.00M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $463.00K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $6.31M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |